CLINICAL_TRIALS
trial_result
· 2020-09-04
Clinical Trial Update: Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis [Phase 2]
Summary
Phase 2 trial update for mapracorat ophthalmic formulation in subjects with allergic conjunctivitis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bausch & Lomb Incorporated | Conditions: Conjunctivitis, Allergic | Phase 2 | Status: COMPLETED | Results posted: 2020-09-04